<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01194804</url>
  </required_header>
  <id_info>
    <org_study_id>E07-001</org_study_id>
    <nct_id>NCT01194804</nct_id>
  </id_info>
  <brief_title>E07-001: Safety and Efficacy Extension Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients</brief_title>
  <official_title>Phase II Clinical Study of Eculizumab (h5G1.1-mAb) in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients: Extension Study to C07-001 Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CMIC Co, Ltd. Japan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the long term safety of Eculizumab in hemolytic PNH
      patients who completed the 4 weeks screening and 12 weeks treatment period of C07-001 study.
      In addition, pharmacokinetic and pharmacodynamic assessments of Eculizumab will be conducted.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Efficacy of Eculizumab treatment</measure>
    <time_frame>Baseline through Week 26</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of LDH</measure>
    <time_frame>From baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of total scores of FACIT-Fatigue scale</measure>
    <time_frame>From baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of PNH RBC</measure>
    <time_frame>From baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of units of Packed RBCs transfused</measure>
    <time_frame>From baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lactate dehydrogenase (LDH) area under the curve (AUC)</measure>
    <time_frame>From baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of plasma free Hemoglobin</measure>
    <time_frame>From baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of total EORTC QLQ-C30 score</measure>
    <time_frame>From baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Paroxysmal Nocturnal Hemoglobinuria</condition>
  <arm_group>
    <arm_group_label>Eculizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with eculizumab for patients with PNH who have successfully completed the C07-001 protocol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eculizumab</intervention_name>
    <description>Each vial contains 30 mL of 10 mg/mL eculizumab; dose of 900 mg intravenous every 14 days.</description>
    <arm_group_label>Eculizumab</arm_group_label>
    <other_name>Soliris</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have fully completed C07-001 study 12-week treatment period

        Exclusion Criteria:

          -  Patients who terminated early from the C07-001 study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2010</study_first_submitted>
  <study_first_submitted_qc>September 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2010</study_first_posted>
  <last_update_submitted>February 15, 2017</last_update_submitted>
  <last_update_submitted_qc>February 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemolytic Paroxysmal Nocturnal Hemoglobinuria</keyword>
  <keyword>Eculizumab</keyword>
  <keyword>PNH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemoglobinuria</mesh_term>
    <mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>November 6, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

